Jenburkt Pharmaceuticals Ltd — Others, 18-07-2025: AGM/EGM

Jenburkt Pharmaceuticals held its 40th Annual General Meeting virtually. Key discussions covered the company's 40-year growth, FY2024-25 performance in India and internationally, and the reorganization of pharma divisions into NOVA and ZORA. Strategic tie-ups and focus on innovation, AI integration, and sustainability were highlighted. Shareholders approved the audited financial statements, a dividend of ₹18.00 (180%) per equity share, and the re-appointment of Shri Ashish U. Bhuta as Director and Chairman & Managing Director. Appointments of Secretarial and Cost Auditors were also approved.